Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
| ▸ | IDO1 | P14902 | 2/20 | 0.48 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA5A | P35218 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3204291 | 0.81 | L3MBTL1 (0.51) | TSHRALDH1A1GAAMAPT | |
| SCHEMBL28858018 | 0.81 | TAAR1 (0.75) | TAAR1SIGMAR1AOC3KCNH2HRH3 | |
| SCHEMBL834561 | 0.81 | TAAR1 (0.58) | TAAR1SIGMAR1AOC3KCNH2HRH3 | |
| SCHEMBL3299435 | 0.80 | TSHR (0.38) | TAAR1TSHRSIGMAR1AOC3KCNH2 | |
| SCHEMBL198463 | 0.80 | IDO1 (0.52) | TAAR1TSHRSIGMAR1AOC3IDO1 | |
| SCHEMBL8764227 | 0.79 | MEN1 (0.52) | TSHRALDH1A1 | |
| SCHEMBL3217269 | 0.78 | KMT2A (0.45) | TAAR1TSHRCA12CA1CA2 | |
| SCHEMBL13531144 | 0.78 | CYP1A2 (0.49) | TSHRALDH1A1MAPT | |
| SCHEMBL28399606 | 0.77 | TSHR (0.43) | TAAR1TSHRCHRM2CHRM1CHRM3 | |
| SCHEMBL7831226 | 0.77 | TAAR1 (0.69) | TAAR1SIGMAR1AOC3KCNH2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114248574-A | Application of thermo-reversible piezochromic dye in inkless printing technology | 天津理工大学 | 2022-03-29 | — | — | CN | claimed |
| CN-107200729-B | Preparation method of 4- (2-methoxyphenyl) -5- (2-pyridyl) -3-aminoisoxazole | 无锡捷化医药科技有限公司 | 2020-03-17 | — | — | CN | claimed |
| CN-114248574-A | Application of thermo-reversible piezochromic dye in inkless printing technology | 天津理工大学 | 2022-03-29 | — | — | CN | disclosed |
| CN-112830931-A | Process for the preparation of asenapine | 浙江奥翔药业股份有限公司 | 2021-05-25 | — | — | CN | disclosed |
| CN-110606852-B | Process for the preparation of asenapine | 浙江奥翔药业股份有限公司 | 2021-02-05 | — | — | CN | disclosed |
| CN-109485757-B | Polypropylene containing nitrile group and preparation method thereof | 江苏中煦聚烯烃研究院有限公司 | 2021-01-12 | — | — | CN | disclosed |
| CN-107200729-B | Preparation method of 4- (2-methoxyphenyl) -5- (2-pyridyl) -3-aminoisoxazole | 无锡捷化医药科技有限公司 | 2020-03-17 | — | — | CN | disclosed |
| CN-110606852-A | Process for the preparation of asenapine | 浙江奥翔药业股份有限公司 | 2019-12-24 | — | — | CN | disclosed |
| US-9868707-B2 | Small molecule agonists of neurotensin receptor 1 | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2018-01-16 | — | — | US | disclosed |
| US-20150329497-A1 | SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1 | DUKE UNIVERSITY (US) | 2015-11-19 | — | — | US | disclosed |
| US-20140221371-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-08-07 | — | — | US | disclosed |
| US-7420053-B2 | 2-imino-1,3-thiazine derivatives | SHIONOGI & CO., LTD. (JP) | 2008-09-02 | — | — | US | disclosed |
| EP-1917245-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | Abbott GmbH & Co. KG (DE) | 2008-05-07 | — | — | EP | disclosed |
| WO-2007022946-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | ABBOTT GMBH & CO. KG (DE) | 2007-03-01 | — | — | WO | disclosed |
| US-6326500-B1 | ANTIINFLAMMATORY AGENTS; ANTIALLERGENS | ABBOTT LABORATORIES | 2001-12-04 | — | — | US | disclosed |
| US-6215001-B1 | ANTIINFLAMMATORY AGENTS, ANTIASTHMATICS, AND ANTIALLERGENS; SIDE EFFECT REDUCTION | KNOLL AKTIENGESELLSCHAFT (DE) | 2001-04-10 | — | — | US | disclosed |
| US-6031109-A | Phenoxy-, phenylthio-, benzoyl-alkyleneaminoalkylene-imidazole derivatives as therapeutic agents | KNOLL AKTIENGESELLSCHAFT (DE) | 2000-02-29 | — | — | US | disclosed |
| US-5780642-A | NON-STEROIDAL ANTIINFLAMMATORY AGENT WHICH BLOCKS RELEASE OF ARACHIDONIC ACID FROM PHOSPHOLIPIDS; SIDE EFFECT REDUCTION | KNOLL AKTIENGESELLSCHAFT (DE) | 1998-07-14 | — | — | US | disclosed |
| EP-0705251-A1 | IMIDAZOLE DERIVATIVES AS THERAPEUTIC AGENTS | Knoll AG (DE) | 1996-04-10 | — | — | EP | disclosed |
| WO-1995000493-A1 | IMIDAZOLE DERIVATIVES AS THERAPEUTIC AGENTS | KNOLL AG (DE) | 1995-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221371-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | HTR5A, HTR1A, HTR2C | TAAR1 45/4885TSHR 412/4885SIGMAR1 279/4885 |
| US-20150329497-A1 | SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1 | NTSR1, NTSR2, VIPR1 | TAAR1 46/4885TSHR 62/4885SIGMAR1 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.